Tirzepatide suicidal ideation risk lower in adults with obesity and depression in records study

Adults with obesity and major depression who started tirzepatide had fewer recorded episodes of suicidal ideation than similar adults who started other obesity drugs, a study in Translational Psychiatry reports. The tirzepatide suicidal ideation result, published on October 25, comes from health records rather than a randomized trial. The authors, based in Taiwan, stress that the association does not show the drug prevents suicidal thoughts. The study adds to a safety question that the FDA has already reviewed across the GLP 1 class.

What the Translational Psychiatry study found

The team used deidentified electronic health records from the TriNetX Global Collaborative Network, a large research database drawn from health care organizations. It selected adults with diagnosed obesity and major depressive disorder who began tirzepatide, or who began an anti obesity medicine that is not a GLP 1 receptor agonist. The paper's abstract does not name those comparison drugs. The two groups were matched on recorded characteristics using propensity scores, leaving 24,103 pairs. The primary outcome was a recorded diagnosis of suicidal ideation. Secondary outcomes were anxiety disorders, insomnia disorders, death from any cause, and visits to an emergency department or admissions to hospital.

Tirzepatide users had a 37 percent lower hazard of recorded suicidal ideation, with a hazard ratio of 0.63 and a 95 percent confidence interval from 0.42 to 0.93. Anxiety and insomnia diagnoses were also less frequent, and so were emergency visits or hospital stays. The largest gap was in deaths, with a hazard ratio of 0.38. The authors report that results were broadly consistent across prespecified subgroups and that control outcome analyses supported the internal validity of the study. A hazard ratio compares the rate of an event over time between two groups; a value below 1 means the event was recorded less often in the tirzepatide group.

Who ran the study and how to read it

The paper is by Ting-Hui Liu, Chia-Chun Chu and colleagues at Chi Mei Medical Center in Tainan, with coauthors from National Defense Medical University, Tri-Service General Hospital and other Taiwanese institutions. The corresponding authors are Hsin-An Chang and Chih-Cheng Lai. It was funded by Taiwan's National Science and Technology Council and a joint Chi Mei and National Defense Medical University project, and the authors declare no competing interests. The Chi Mei review board approved the work. The journal received the paper in February 2026 and accepted it in September. The Translational Psychiatry paper is open access, and its abstract states the main results and caveats in plain terms.

The authors write that the observational association should not be read as evidence of a direct antisuicidal effect.

The authors write that the observational association should not be read as evidence of a direct antisuicidal effect. That caution matters. Records capture only what clinicians write down, so suicidal thoughts that were never reported or coded are invisible. Matching balances measured factors but cannot balance unmeasured ones, such as how sick, how well supported or how engaged with care each patient was. The very large difference in deaths is a reason for care. In record based studies, gaps of that size between treatment groups can signal that the groups still differ in health in ways the matching did not remove. Randomized trials are the only way to rule that out.

What the FDA concluded about GLP 1 drugs

Regulators have looked at this question at the class level. In January 2024, the FDA said its preliminary evaluation had found no evidence that GLP 1 receptor agonists cause suicidal thoughts or actions, while noting that it could not rule out a small risk. On January 13, 2026, the agency went further. In a drug safety communication, it asked the makers of Saxenda, Wegovy and Zepbound to remove the warning on suicidal behavior and ideation from their labels. GLP 1 drugs approved only for type 2 diabetes never carried that warning. Zepbound is the obesity brand of tirzepatide, so the request covers the drug in the new study.

The FDA based its decision on a meta analysis of 91 placebo controlled trials with 107,910 patients, which found no increased risk of suicidal ideation or behavior or of related psychiatric events. It also used a Sentinel cohort study of more than 2.2 million new users, comparing GLP 1 drugs with SGLT2 inhibitors, which found no increased risk of intentional self harm. The agency said the totality of the studies does not support a causal link. It still advises patients to report new or worsening depression, suicidal thoughts or unusual changes in mood to a clinician, and points people in crisis in the United States to the 988 Suicide and Crisis Lifeline.

What this means for the tirzepatide suicidal ideation question

The new study points in the same direction as the FDA review, and it focuses on a group at higher risk: people who already live with major depression. That focus is its main contribution. It does not show that tirzepatide treats depression or protects against suicide, and the authors do not claim it does. Their conclusion is that tirzepatide may be a metabolically favorable option associated with lower recorded risk in this group. The tirzepatide suicidal ideation signal, in other words, now looks reassuring rather than alarming, but the evidence is observational and comes from records collected for care, not research.

Several questions remain open. The abstract does not say how long people were followed, which comparison drugs were used, or how many people in each group had a recorded event. Those details are in the full paper and supplement, and they shape how much the hazard ratios can be trusted. People taking any obesity drug who notice changes in mood should talk to their prescriber and should not stop or start treatment on the basis of one study. Our safety desk follows side effect reviews for peptide medicines. This story is for information only and is not medical advice, as set out in our site disclaimer.

Conclusion

A large record based study from Taiwanese researchers links tirzepatide to fewer recorded cases of suicidal ideation in adults with obesity and major depression. It fits the FDA's 2026 decision that GLP 1 drugs do not raise this risk. The tirzepatide suicidal ideation finding is still an association. Randomized trials in people with depression would be needed to show cause and effect, and clinicians are still advised to watch mood closely.